ImageneBio Inc IMA
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-26 |
| Shares Out. | 11,280,000 |
| Website | inmagenebio.com/ ↗ |
| Phone | 18573438292 |
| Employees | 18 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$10.2M |
| Free Cash Flow | -$57.7M |
| Total Assets | $152.0M |
| Total Liabilities | $10.0M |
| Equity | $142.1M |
About ImageneBio Inc
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
ImageneBio Inc is a publicly traded company under the ticker symbol IMA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)